AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22658512 — intervention group
Group type: COMPARATOR
Intervention: Late salvage hormonal therapy (distant metastases)
Number of subjects: 102
Study 21613439 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous disk decompression (PDD)
Number of subjects: 31
Study 21613439 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 31
Study 19028742 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-field digital retinal imaging (WFDRI)
Number of subjects: 81
Study 19028742 — intervention group
Group type: COMPARATOR
Intervention: Binocular indirect ophthalmoscopy (BIO)
Number of subjects: 81
Study 16448282 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid + primer + composite + conventional Victory bracket
Number of subjects: 23
Study 16448282 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid + primer + precoated Victory bracket
Number of subjects: 23
Study 16448282 — intervention group
Group type: EXPERIMENTAL
Intervention: SEP + composite + conventional bracket
Number of subjects: 23
Study 16448282 — intervention group
Group type: EXPERIMENTAL
Intervention: SEP + precoated bracket
Number of subjects: 23
Study 14985515 — intervention group
Group type: EXPERIMENTAL
Intervention: Congested streets
Number of subjects: 448
Study 14985515 — intervention group
Group type: COMPARATOR
Intervention: Uncongested streets
Number of subjects: 448
Study 11737404 — intervention group
Group type: COMPARATOR
Intervention: Standard trial information (SI) alone (n = 27)
Number of subjects: 50
Study 11737404 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard trial information (SI) plus a 16 page information booklet (n = 23)
Number of subjects: 50
Study 11737404 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SI and SI plus booklet)
Number of subjects: 50
Study 9914274 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal transcranial magnetic stimulation of the motor cortex during voluntary ankle dorsiflexion (TA)
Number of subjects: 0
Study 9914274 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal transcranial magnetic stimulation of the motor cortex during stance phase of walking (soleus)
Number of subjects: 0
Study 9914274 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal transcranial magnetic stimulation of the motor cortex during stance phase of walking (inactive TA)
Number of subjects: 0
Study 9914274 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal transcranial magnetic stimulation of the motor cortex at various phases of the step cycle
Number of subjects: 0
Study 8084974 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 14
Study 8084974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2666080 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent tablets A (161 mg daily)
Number of subjects: 24
Study 2666080 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent tablets A* (161 mg daily)
Number of subjects: 24
Study 2666080 — intervention group
Group type: COMPARATOR
Intervention: Proprietary iron preparation B (150 mg daily)
Number of subjects: 24
Study 909253 — intervention group
Group type: EXPERIMENTAL
Intervention: Euthyscope followed by occlusion
Number of subjects: 63
Study 909253 — intervention group
Group type: COMPARATOR
Intervention: Occlusion
Number of subjects: 63
Study 909253 — intervention group
Group type: EXPERIMENTAL
Intervention: Euthyscope treatment
Number of subjects: 63
Study 909253 — intervention group
Group type: COMPARATOR
Intervention: Comparison of amblyopes with anisometropic and microstrabismic patients
Number of subjects: 63
Study 909253 — intervention group
Group type: COMPARATOR
Intervention: Refraction in amblyopic eyes
Number of subjects: 63
Study 31906948 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 440
Study 31906948 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 440
Study 31906948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo susceptibility to monodesethylamodiaquine
Number of subjects: 440
Study 31906948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumefantrine and monodesethylamodiaquine
Number of subjects: 440
Study 31906948 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 440
Study 31264138 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Number of subjects: 0
Study 31264138 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine U100
Number of subjects: 0
Study 28793772 — intervention group
Group type: EXPERIMENTAL
Intervention: HSFA diet, rich in saturated fat
Number of subjects: 75
Study 28793772 — intervention group
Group type: COMPARATOR
Intervention: HMUFA diet, rich in monounsaturated fat
Number of subjects: 75
Study 28793772 — intervention group
Group type: COMPARATOR
Intervention: LFHCC n‐3 diet, low-fat, rich in complex carbohydrate supplemented with n‐3 polyunsaturated fatty acids
Number of subjects: 75
Study 28793772 — intervention group
Group type: COMPARATOR
Intervention: LFHCC low-fat diet, rich in complex carbohydrate supplemented with placebo
Number of subjects: 75
Study 25294839 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical vibration (VV)
Number of subjects: 61
Study 25294839 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-alternating vibration (SV)
Number of subjects: 61
Study 25294839 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 61
Study 23518443 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 250
Study 23518443 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% Salicylic acid self-application
Number of subjects: 250
Study 23518443 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see policy
Number of subjects: 250
Study 21636861 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m(2) weekly for 4 weeks
Number of subjects: 40
Study 21636861 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (no rituximab)
Number of subjects: 40
Study 18834692 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT participants
Number of subjects: 0
Study 18834692 — intervention group
Group type: COMPARATOR
Intervention: Treatment seekers
Number of subjects: 0
Study 16247584 — intervention group
Group type: COMPARATOR
Intervention: Biodex Stability System at level 8
Number of subjects: 74
Study 16247584 — intervention group
Group type: COMPARATOR
Intervention: Biodex Stability System at level 2
Number of subjects: 74
Study 14993771 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (4 mg iv and 4 mg ic before reperfusion, followed by continuous infusion at 4 mg/h for 24 h)
Number of subjects: 40
Study 14993771 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (10 mmol iv before reperfusion, followed by continuous infusion at 0.4 mmol/h for 24 h)
Number of subjects: 40
Study 14993771 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 11782040 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined estimator for the variance of the treatment effect estimator
Number of subjects: 0
Study 11782040 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed test for overall treatment effect
Number of subjects: 0
Study 11782040 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of controlled multi-centre study with binary outcome
Number of subjects: 0
Study 9293679 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucralfate in sorbolene cream
Number of subjects: 39
Study 9293679 — intervention group
Group type: COMPARATOR
Intervention: Sorbolene alone
Number of subjects: 39
Study 9293679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 39
Study 9300326 — intervention group
Group type: EXPERIMENTAL
Intervention: SNX‐111 (neuron-specific, N-type, voltage-sensitive calcium channel blocker)
Number of subjects: 0
Study 2527274 — intervention group
Group type: EXPERIMENTAL
Intervention: rHBV vaccine (2 micrograms)
Number of subjects: 482
Study 2527274 — intervention group
Group type: EXPERIMENTAL
Intervention: rHBV vaccine (5 micrograms)
Number of subjects: 482
Study 2527274 — intervention group
Group type: EXPERIMENTAL
Intervention: rHBV vaccine (10 micrograms)
Number of subjects: 482
Study 2527274 — intervention group
Group type: EXPERIMENTAL
Intervention: rHBV vaccine (20 micrograms)
Number of subjects: 482
Study 2527274 — intervention group
Group type: COMPARATOR
Intervention: plasma-derived hepatitis B virus vaccine (Hevac B Pasteur)
Number of subjects: 482
Study 2527274 — intervention group
Group type: EXPERIMENTAL
Intervention: rHBV vaccine (10 and 20 micrograms)
Number of subjects: 482
Study 2527274 — intervention group
Group type: EXPERIMENTAL
Intervention: rHBV vaccine
Number of subjects: 482
Study 1106927 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor therapy (equivalent to 2‐1 X 10(8) leucocytes)
Number of subjects: 30
Study 1106927 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 30803309 — intervention group
Group type: EXPERIMENTAL
Intervention: Ving Tsun (VT) training, 2 sessions per week for 3 months (24 sessions)
Number of subjects: 33
Study 30803309 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 27989407 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention including 6 nurse-led individual face-to-face and telephone counseling sessions within 1 month and a voluntary face-to-face family counseling session (FCS)
Number of subjects: 1158
Study 27989407 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention including FCS
Number of subjects: 1158
Study 27989407 — intervention group
Group type: COMPARATOR
Intervention: Control group received a leaflet, a self-help booklet, and brief quitting advice only
Number of subjects: 1158
Study 26598475 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (RISP)
Number of subjects: 279
Study 26598475 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (LI)
Number of subjects: 279
Study 26598475 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium (VAL)
Number of subjects: 279
Study 26598475 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (RISP, LI, VAL)
Number of subjects: 279
Study 23463179 — intervention group
Group type: EXPERIMENTAL
Intervention: New Forest Parenting Programme Self‐help (NFPP‐SH)
Number of subjects: 43
Study 23463179 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 43
Study 22112960 — intervention group
Group type: EXPERIMENTAL
Intervention: Management by a specialist multidisciplinary team for six weeks according to a care plan agreed between the professionals and the patient and carer (Group A)
Number of subjects: 0
Study 22112960 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team management and additional support for four months from a trained care assistant (Group B)
Number of subjects: 0
Study 22112960 — intervention group
Group type: COMPARATOR
Intervention: Usual care, no coordinated team care planning or ongoing support (Group C)
Number of subjects: 0
Study 19697823 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-Classic
Number of subjects: 50
Study 19697823 — intervention group
Group type: COMPARATOR
Intervention: COBRA-PLA
Number of subjects: 50
Study 19697823 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 50
Study 16469987 — intervention group
Group type: COMPARATOR
Intervention: Apples fortified with deuterium-labeled alpha-tocopheryl acetate at 0% fat
Number of subjects: 5
Study 16469987 — intervention group
Group type: EXPERIMENTAL
Intervention: Apples fortified with deuterium-labeled alpha-tocopheryl acetate at 6% fat
Number of subjects: 5
Study 16469987 — intervention group
Group type: EXPERIMENTAL
Intervention: Apples fortified with deuterium-labeled alpha-tocopheryl acetate at 21% fat
Number of subjects: 5
Study 16469987 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 5
Study 15282428 — intervention group
Group type: EXPERIMENTAL
Intervention: ACIST Injection System (automated contrast injection)
Number of subjects: 453
Study 15282428 — intervention group
Group type: COMPARATOR
Intervention: Manual injection (control group)
Number of subjects: 453
Study 11302274 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Family Management (AFM) including 1 year of behavioral family therapy plus support groups for 2 years
Number of subjects: 0
Study 11302274 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Family Management (SFM) including monthly support groups for 2 years
Number of subjects: 0
Study 11302274 — intervention group
Group type: COMPARATOR
Intervention: Standard, low, targeted neuroleptic dosage strategies
Number of subjects: 0
Study 11302274 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-limited behavioral family therapy added to monthly support groups
Number of subjects: 0
Study 9531235 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based smoking intervention consisting of a 15-minute bedside counseling session, written self-help material, a chart prompt for physicians, and up to 3 weekly counseling telephone calls after discharge.
Number of subjects: 650
Study 9531235 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 650
Study 9531235 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based smoking intervention.
Number of subjects: 650
Study 9531235 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based smoking intervention among patients who had not previously tried to quit smoking.
Number of subjects: 650
Study 9531235 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) among patients who had not previously tried to quit smoking.
Number of subjects: 650
Study 8103527 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam mesylate (n = 15)
Number of subjects: 33
Study 8103527 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (n = 18)
Number of subjects: 33
Study 3513596 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-releasing zinc polycarboxylate cement
Number of subjects: 180
Study 3513596 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-releasing glass ionomer cement
Number of subjects: 180
Study 3513596 — intervention group
Group type: COMPARATOR
Intervention: Standard orthodontic cement zinc phosphate
Number of subjects: 180
Study 29735284 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening intervention (60 minutes, twice a day, over three days)
Number of subjects: 40
Study 27479951 — intervention group
Group type: EXPERIMENTAL
Intervention: Telestroke intervention
Number of subjects: 2657
Study 24344111 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% Hypertonic saline with epinephrine
Number of subjects: 101
Study 24344111 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline with epinephrine (Control)
Number of subjects: 101
Study 22075478 — intervention group
Group type: EXPERIMENTAL
Intervention: autotitrating continuous positive airway pressure (autoCPAP) in autotitrating mode
Number of subjects: 34
Study 22075478 — intervention group
Group type: COMPARATOR
Intervention: fixed subtherapeutic pressure (detection assessment)
Number of subjects: 34
Study 19892350 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin 6 mg/day
Number of subjects: 61
Study 19892350 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin 12 mg/day
Number of subjects: 61
Study 19892350 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin 18 mg/day
Number of subjects: 61
Study 19892350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 18033318 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 209
Study 18033318 — intervention group
Group type: COMPARATOR
Intervention: HLA-matched sibling transplantation
Number of subjects: 209
Study 15988245 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injections
Number of subjects: 36
Study 12464836 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aloe vera gel
Number of subjects: 225
Study 12464836 — intervention group
Group type: COMPARATOR
Intervention: Topical aqueous cream
Number of subjects: 225
Study 10499484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholylsarcosine 6 g/day
Number of subjects: 4
Study 10499484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholylsarcosine 12 g/day
Number of subjects: 4
Study 10499484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholylsarcosine
Number of subjects: 4
Study 7565257 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric emptying plus activated charcoal (E group)
Number of subjects: 876
Study 7565257 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal alone (NE group)
Number of subjects: 876
Study 1941185 — intervention group
Group type: EXPERIMENTAL
Intervention: Leavened whole-wheat bread
Number of subjects: 0
Study 1941185 — intervention group
Group type: COMPARATOR
Intervention: Milk
Number of subjects: 0
Study 1941185 — intervention group
Group type: EXPERIMENTAL
Intervention: Leavened whole-wheat bread with milk
Number of subjects: 0
Study 1941185 — intervention group
Group type: EXPERIMENTAL
Intervention: Extruded cereal from intrinsically labeled wheat bran
Number of subjects: 0
Study 1941185 — intervention group
Group type: EXPERIMENTAL
Intervention: Extruded cereal with milk
Number of subjects: 0
Study 1941185 — intervention group
Group type: EXPERIMENTAL
Intervention: Leavened bread
Number of subjects: 0
Study 1941185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cookies (underbaked and overbaked)
Number of subjects: 0
Study 6379529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal biophysical profile scoring
Number of subjects: 735
Study 6379529 — intervention group
Group type: COMPARATOR
Intervention: Nonstress testing
Number of subjects: 735
Study 29504440 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise program (n = 133)
Number of subjects: 262
Study 29504440 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 129)
Number of subjects: 262
Study 31487290 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased language ability
Number of subjects: 200
Study 31487290 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor language ability (bottom 10% of sample)
Number of subjects: 200
Study 28542080 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-Care Testing (POCT)
Number of subjects: 432
Study 28542080 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 432
Study 27668927 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 288
Study 27668927 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of daily living (Katz ADL)
Number of subjects: 288
Study 27668927 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of dementia
Number of subjects: 288
Study 27668927 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric disorders
Number of subjects: 288
Study 27668927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary diseases
Number of subjects: 288
Study 27668927 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric symptoms
Number of subjects: 288
Study 27668927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 288
Study 25118999 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 33
Study 25118999 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 33
Study 25118999 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 33
Study 22236534 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 284
Study 22236534 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous cholecystostomy
Number of subjects: 284
Study 19108877 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (50 mg/m(2)) and Doxorubicin (45 mg/m(2))
Number of subjects: 552
Study 19108877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (50 mg/m(2)), Doxorubicin (45 mg/m(2)), and Paclitaxel (160 mg/m(2))
Number of subjects: 552
Study 19108877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, Doxorubicin, and Paclitaxel
Number of subjects: 552
Study 19108877 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and Doxorubicin
Number of subjects: 552
Study 17339482 — intervention group
Group type: EXPERIMENTAL
Intervention: FH purified from sera of AMD patients homozygous for the FH(402H) variant
Number of subjects: 2
Study 17339482 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant fragment of FH (short consensus repeat 5-7) containing the FH(402H) variant
Number of subjects: 2
Study 17339482 — intervention group
Group type: COMPARATOR
Intervention: FH derived from unaffected controls homozygous for the FH(402Y) variant
Number of subjects: 2
Study 15129404 — intervention group
Group type: COMPARATOR
Intervention: RBS
Number of subjects: 22
Study 15129404 — intervention group
Group type: EXPERIMENTAL
Intervention: PBS+RBS
Number of subjects: 22
Study 11824175 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous dose of porcine secretin
Number of subjects: 12
Study 11824175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9510221 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-session experimental group intervention
Number of subjects: 97
Study 9510221 — intervention group
Group type: COMPARATOR
Intervention: 2-session control intervention
Number of subjects: 97
Study 7992097 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interferon-alpha 2a (rIFN-alpha 2a)
Number of subjects: 0
Study 7992097 — intervention group
Group type: COMPARATOR
Intervention: standard hydroxyurea chemotherapy
Number of subjects: 0
Study 2662999 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous natural surfactant treatment
Number of subjects: 0
Study 2662999 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic surfactant treatment at birth
Number of subjects: 0
Study 2662999 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bovine surfactant
Number of subjects: 0
Study 5494682 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolazoline hydrochloride
Number of subjects: 5
Study 5494682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30193253 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-supported n-of-1 trial
Number of subjects: 215
Study 30193253 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 215